RESUMO
BACKGROUND:Mesenchymal stem cells from human skeletal muscle exhibit multi-directional differentiation potential under the influence of osteogenic proteins such as bone morphogenetic protein 4 (BMP4). But the differentiation of a specific cell subpopulation is not yet clear.OBJECTIVE:To characterize the multi-directional differentiation potential of mesenchymal stem cells from human skeletal muscle based on the expression of different surface markers.METHODS:Four different subpopulations were isolated from the human skeletal muscle by fluorescence-activated cell sorting based on their expression of the myogenic-specific marker CD56 and the endothelial-specific markers CD34 and CD144, including CD56+, CD56+CD34+CD144+, CD34+CD144+, and unsorted groups. Osteogenic differentiation of the four groups of the cells was displayed by Von Kossa staining after the treatment with BMP4 alone or BMP4 plus transforming growth factor β3. Chondrogenic differentiation of these cells was displayed by Alcian blue staining. Bone metabolism was assessed by alkaline phosphatase staining.RESULTS AND CONCLUSION:No significant difference in the bone metabolism was found among four groups after the treatment with BMP4 (P > 0.05). Osteogenic and chondrogenic potentials of the four cell subpopulations were significantly different. Under the same osteogenic induction, the CD56+ cells exhibited strongest potential for osteogenic differentiation; and under the same chondrogenic induction, the CD56+CD34+CD144+ cells exhibited better potential for chondrogenic differentiation than the CD56+ cells. These findings indicate that the osteogenic and chondrogenic potentials are intimately associated with the type of mesenchymal stem cells from human skeletal muscle:the CD56+ cells are closely related to the osteogenic potential, while the CD56+CD34+CD144+ cells have stronger chondrogenic potential.
RESUMO
Objective To observe effects of theYubaisang-Zhikefangdecoction on chronic bronchitis.MethodsA total of 128 patients were randomly divided into two groups. The control group was given the conventional therapy, and the treatment group was added theYubaisang-Zhikefang decoction based on the conventional therapy.ResultsThe total effective rate of treatment group was significantly better than the control group (92.58%vs. 79.37%;χ2=4.434,P=0.035). The treatment group significantly improved the symptoms of time of cough disappearance(3.28 ± 1.21 d vs. 5.77 ± 1.45 d;t=10.562,P<0.05), time of asthma stop (8.02 ± 3.29d vs. 10.83 ± 7.17 d;t=2.864,P<0.05), time of sputum disappearance (3.27 ± 1.18d vs. 5.18 ± 1.16 d;t=9.232,P<0.05), time of moist sounds disappearance(4.53 ± 1.27 vs. 7.96 ± 1.45 d;t=14.249, P<0.05). And the treatment group significantly improved the results of blood tests and lung imaging, like the WBC (5.9×109/L ± 2.7×109/L vs. 8.1×109/L ± 2.6×109/L;t=4.693,P<0.05), N% (63.3% ± 6.1% vs. 69.2% ± 6.5%;t=-4.68,P<0.05), CRP (14.5 ± 5.9 mg/L vs. 18.4 ± 4.8 mg/L;t=5.297,P<0.05).ConclusionThe integrated treatment ofYubaisang-Zhikefangdecoction plus convertional the rapy showed good effects on the patients with chronic bronchitis.